This is a revised application for renewal of the SPORE in Prostate Cancer at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Cancer Research Center of the University of Chicago. Overall, the reviewers noted that the Program had considerable merit with strengths in the expertise of the investigators, large patient population and an environment highly supportive of the SPORE. We have responded to the comments made by the review committee through extensive revisions and, thus, have further enhanced the program throughout. The major changes can be found in Project 4 where we now focus on animal studies and a clinical trial and in Project 2 where we have eliminated one aim to conduct animal studies. The revised application contains four highly translational research projects: (1) 5a-Reductase Inhibition in Intermittent Androgen Ablation Therapy of Prostate Cancer (Wang &Shevrin), (2) PEDF Regulation of Adipogenesis and Leptin in Prostate Cancer (Crawford, Gapstur and Lee), (3) Radiation-lnducible TNF-alpha Therapy in Prostate Cancer (Weichselbaum &Stadler) and (4) Modulation of Prostate Cancer Cell Motility by the Chemopreventive Agent Genistein (Bergan &Catalona). These projects represent a balanced approach in prostate cancer translational research, including prevention (Project 4), molecular epidemiology (Project 2), management of androgen-sensitive advanced cancer (Project 1), and therapy of local disease (project 3). The leadership of the SPORE emphasizes the highly interactive structures in place for the proposed four cores, that include the Administrative Core, the Specimen Procurement Core, the Biostatistics/Bioinformatics Core, and the Clinical Trials and Advocacy Core. The SPORE also has flexible, yet structured, Developmental Research and Career Development Programs to encourage additional investigators to undertake initiatives in prostate cancer research and to quickly respond to new research opportunities. The Internal and External Advisory Committees evaluate program progress and offer guidance to the SPORE principal investigator and co-principal investigators. We feel that the revised application is significantly improved, and we are grateful to the reviewers for their helpful comments.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (O1))
Program Officer
Hruszkewycz, Andrew M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northwestern University at Chicago
Schools of Medicine
United States
Zip Code
Pascal, Laura E; Masoodi, Khalid Z; Liu, June et al. (2017) Conditional deletion of ELL2 induces murine prostate intraepithelial neoplasia. J Endocrinol 235:123-136
Dominguez, Donye; Ye, Cong; Geng, Zhe et al. (2017) Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer. J Immunol 198:1365-1375
Murphy, A B; Nyame, Y A; Batai, K et al. (2017) Does prostate volume correlate with vitamin D deficiency among men undergoing prostate biopsy? Prostate Cancer Prostatic Dis 20:55-60
Zhang, Minghui; Dominguez, Donye; Chen, Siqi et al. (2017) WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability. Oncol Lett 14:3580-3586
Hung, Michelle E; Leonard, Joshua N (2016) A platform for actively loading cargo RNA to elucidate limiting steps in EV-mediated delivery. J Extracell Vesicles 5:31027
Nyame, Yaw A; Murphy, Adam B; Bowen, Diana K et al. (2016) Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy. J Clin Oncol 34:1345-9
Anderson, Blake B; Oberlin, Daniel T; Razmaria, Aria A et al. (2016) Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer. Eur Urol :
Kregel, Steven; Chen, James L; Tom, Westin et al. (2016) Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer. Oncotarget 7:26259-74
Ye, Cong; Geng, Zhe; Dominguez, Donye et al. (2016) Targeting Ornithine Decarboxylase by ?-Difluoromethylornithine Inhibits Tumor Growth by Impairing Myeloid-Derived Suppressor Cells. J Immunol 196:915-23
Jin, Hong-Jian; Jung, Segun; DebRoy, Auditi R et al. (2016) Identification and validation of regulatory SNPs that modulate transcription factor chromatin binding and gene expression in prostate cancer. Oncotarget 7:54616-54626

Showing the most recent 10 out of 201 publications